Merck's Keytruda finds a path in ovarian cancer with phase 3 win in certain recurrent patients
Merck's cancer superstar Keytruda has not yet been able to add an ovarian cancer-specific nod to its impressive lineup of approved indications. Now, the drug has shown benefits for patients with platinum-resistant recurrent ovarian cancer.
Merck's cancer superstar Keytruda has not yet been able to add an ovarian cancer-specific nod to its impressive lineup of approved indications. Now, the drug has shown benefits for patients with platinum-resistant recurrent ovarian cancer.
